A study found that less than 1 in 1,000 adolescents received gender-affirming medication from 2018 to 2022. Out of over 5 million patients surveyed, 926 received puberty blockers and 1,927 hormones. The study’s release comes amid debates over gender-affirming care laws for minors, with at least 26 states restricting such care. The researchers argue that gender-affirming care isn’t used as much as believed and is essential for psychological functioning.
HIPAA risk analysis gaps lead to 2 HHS enforcement actions
The HHS Office for Civil Rights (OCR) has settled two ransomware investigations involving Elgon Information Systems and Virtual Private Network Solutions, both found to have
